Global Regulatory Engagement Series This executive series provides startup and midsize biotech leaders with actionable, cross-functional blueprints for engaging global regulatory authorities (FDA, EMA, MHRA, PMDA, NMPA) across preclinical, translational, and clinical drug development. Article Sequence Thematic Focus Status Article 1 Navigating the Global Regulatory Matrix: A Strategic Guide to FDA, EMA, MHRA, PMDA, and […]

The Modality Matrix Series Portfolio This sixth installment explores the specialized domain of Targeted Radionuclide Therapies (TRTs) and theranostics. Transitioning these dual-modality assets into first-in-human clinical trials requires an advanced quantitative Clinical Pharmacology Plan (CPP) capable of integrating radiation dosimetry, radioactive decay kinetics, and multi-isotope PBPK modeling. Article Sequence Thematic Focus Status Article 1 Overview